Anders Bach received his PhD in medicinal chemistry from Department of Drug Design and Pharmacology, University of Copenhagen (UCPH) in 2009. He developed compounds against PDZ domains involved in protein-protein interactions in the CNS, and particularly dimeric peptidomimetic compounds against PSD-95, which resulted in the spin-out company Avilex Pharma. He continued as a postdoc at UCPH for some years, until he joined the Italian Institute of Technology, Department of Drug Discovery and Development in Genoa, Italy, in 2012. Here, he worked on covalent small-molecule inhibitors of acid ceramidase and related enzymes involved in lipid metabolism and signalling. Anders now works as associate professor and group leader at UCPH, where he uses fragment-based drug discovery to make new small-molecule inhibitors of protein-protein interactions involved in oxidative stress and inflammation and of importance to the pathophysiology of several diseases.